Skip to main content

Table 6 The average duration of common cold disease in patients of different virus subgroups in days

From: Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials

Patients

Group

hRV

hCV

InfA

ITT

Carrageenan

8.8 ± 0.6

9.02 ± 0.7

8.7 ± 1.0

Placebo

10.7 ± 0.7

12.95 ± 0.99

12.0 ± 1.2

 

Difference

1.9 days*

3.9 days**

3.3 days*

PP

Carageenan

8.7 ± 0.7

9.1 ± 0.7

9 ± 1.1

Placebo

10.5 ± 0.8

12.2 ± 1.1

10.7 ± 1.5

 

Difference

1.8 days*

3.1 days**

1.7 days

  1. *:p < 0.05; **:p < 0.01.
Back to article page

Multidisciplinary Respiratory Medicine

ISSN: 2049-6958

Contact us